Electroporation News and Research

RSS

Streamlining CRISPR workflows, from editing to analysis

INTEGRA's automated solutions optimize CRISPR workflows, enhancing gene editing efficiency and accelerating the path to innovative therapeutic developments.

From INTEGRA Biosciences 30 Sep 2026

Integrated DNA Technologies and Aldevron launch new Cas9 mRNA solutions to accelerate path from gene editing research to development

Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and protein, today announced the launch of research grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats.

From Integrated DNA Technologies 18 Sep 2026

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

Discover how LumiPore improves intracellular delivery with gentle, high-efficiency transfection for drug discovery and cell therapy research.

From Trince 8 Sep 2026

Emerging non-endocytic transmembrane delivery strategies for precision medicine

Conventional endocytosis-mediated delivery is limited by poor endosomal escape efficiency, making intracellular delivery of therapeutic biomacromolecules a long-standing challenge in modern biomedical research.

24 Jul 2026

Single DNA injection provides long-lasting weight loss in mouse study

Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instructions can produce weight loss and blood glucose control in murine models that lasts up to 10 times as long as incretin-mimicking drugs like Ozempic and Wegovy.

26 Jun 2026

How the CDC prepares influenza vaccines for pandemics

CDC scientists outline the comprehensive methodology involved in the development of influenza candidate vaccine viruses.

2 Feb 2026

Electrophysiology-based strategies enhance cancer immunotherapy

Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, and microenvironmental signaling interactions, are critical drivers of malignancy.

17 Aug 2025

New technique enables efficient loading of large biomolecules into exosomes

Exosomes, naturally derived vesicles responsible for intercellular communication, are emerging as next-generation drug delivery systems capable of transporting therapeutics to specific cells.

13 Aug 2025

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

2 Jun 2025

NUS researchers develop breakthrough gene delivery technology for immune cells

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently delivers genetic material into human immune cells.

26 May 2025

New acoustofluidics method transforms intracellular nanoparticle delivery

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle delivery.

7 Mar 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

From MaxCyte, Inc. 13 Feb 2025

New gene modification enhances CAR-T cell effectiveness against cancer

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for an extended period, potentially reducing the chance of cancer recurring.

7 Feb 2025

Study unveils role of TLE6 in male sperm development

Infertility is a major global challenge associated with physiological and psychological impact. Genetic mutations that affect early embryonic development, oocyte (egg cell) maturation, and fertilization have recently been studied as causes of infertility.

16 Jan 2025

Nutrient metabolism regulates T cell exhaustion and therapy potential

Findings reveal that metabolic enzymes ACSS2 and ACLY regulate T cell exhaustion, linking nutrient metabolism to epigenetic changes in immunity.

17 Dec 2024

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.

17 Nov 2024

MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics

From MaxCyte, Inc. 13 Nov 2024

Promising new treatment strategy for type 2 diabetes

Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even eliminate the need for insulin therapy.

14 Oct 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

From MaxCyte, Inc. 23 Sep 2024